Akèy › Kansè ovè › New Mexico › Albuquerque
Etid klinik pou Kansè ovè nan Albuquerque, NM
15 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote Albuquerque (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Ap rekriteFaz 2/3
- University of New Mexico Cancer Center, Albuquerque
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- University of New Mexico Cancer Center, Albuquerque
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Ap rekriteFaz 2
- Optimum Clinical Research Group /ID# 274583, Albuquerque
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Ap rekriteFaz 2
- Research Site, Albuquerque
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ap rekriteFaz 3
- Optimum Clinical Research Group, Albuquerque
Prospective Laboratory Study Biologic Specimens and Tumor Tissue of Patients With Cancer
Ap rekriteEtid obsèvasyon
- University of New Mexico Cancer Center, Albuquerque
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ap rekriteFaz 3
- Unm Comprehensive Cancer Center, Albuquerque
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Albuquerque
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ap rekriteFaz 3
- University of New Mexico Comprehensive Cancer Center ( Site 0055), Albuquerque
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ap rekrite
- University of New Mexico Cancer Center, Albuquerque
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ap rekriteFaz 3
- University of New Mexico Cancer Center, Albuquerque
Clinical Pre-screening Protocol for Ovarian Cancer
Ap rekriteEtid obsèvasyon
- University of New Mexico Comprehensive Cancer, Albuquerque
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Ap rekriteFaz 2
- 292, Albuquerque
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Ap rekriteFaz 3
- University of New Mexico Comprehensive Cancer Center, Albuquerque
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Albuquerque
Etid Kansè ovè nan lòt vil
- Houston, TX89 etid
- New York City, NY69 etid
- Boston, MA61 etid
- Los Angeles, CA50 etid
- Nashville, TN49 etid
- Arlington, VA46 etid
- Philadelphia, PA44 etid
- Columbus, OH39 etid
- St. Louis, MO38 etid
- Chicago, IL36 etid
- San Antonio, TX31 etid
- Cleveland, OH30 etid
Lòt etid nan Albuquerque
- Kansè Poumon ki pa ti selil18 etid
- Kansè nan tete17 etid
- Kansè (tout kalite)14 etid
- Kansè poumon14 etid
- Kansè Metastatik12 etid
- Kansè Endomèt12 etid
- Dyabèt Tip 211 etid
- Maladi kadyovaskilè10 etid
- Melanom9 etid
- Leksemi mieloïd egi9 etid
- Kansè pwostat9 etid
- Maladi ren kwonik8 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.